Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy

被引:29
|
作者
Suzuki, Yuko [1 ]
Kan, Motoyasu [1 ]
Kimura, Gen [1 ]
Umemoto, Kumiko [1 ]
Watanabe, Kazuo [1 ]
Sasaki, Mitsuhito [1 ]
Takahashi, Hideaki [1 ]
Hashimoto, Yusuke [1 ]
Imaoka, Hiroshi [1 ]
Ohno, Izumi [1 ]
Mitsunaga, Shuichi [1 ]
Ikeda, Masafumi [1 ]
机构
[1] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan
关键词
Biliary tract cancer; Prognostic factor; Validation; Chemotherapy; Gemcitabine and cisplatin; TUMOR-INFILTRATING LYMPHOCYTES; PROGNOSTIC-FACTORS; LACTATE-DEHYDROGENASE; PRETREATMENT NEUTROPHIL; PANCREATIC-CANCER; PHASE-III; RATIO; SURVIVAL; JAPAN; INFLAMMATION;
D O I
10.1007/s00535-018-1518-3
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundFew studies have clearly identified the prognostic factors in patients with advanced biliary tract cancer (BTC) receiving gemcitabine plus cisplatin (GC) which is acknowledged as standard chemotherapy regimen.ObjectivesThe aim of this study was to identify predictive factors of the overall survival (OS) in advanced BTC patients receiving GC therapy.MethodsData of 307 patients with advanced BTC who received GC therapy as the first-line chemotherapy at our institution from January 2007 to June 2017 were reviewed retrospectively. The patients were randomly assigned to the investigation or the validation dataset at the ratio of 2:1. Multivariate analysis was conducted to identify the prognostic factors, a prognostic index is proposed from the investigation dataset, and the usefulness of this index was confirmed in the validation dataset.ResultsMultivariate analysis identified poor performance status, elevated serum lactate dehydrogenase, and elevated neutrophil-to-lymphocyte ratio as independent unfavorable predictors. The patients could be classified into three groups according to these factors, and it was found that the outcomes differed significantly among the three groups (P=0.0002, good- vs. intermediate-prognosis groups; P=0.005, intermediate- vs. poor-prognosis groups). When this index was applied to the validation dataset, the OS was confirmed to differ significantly among the three groups (P=0.04, good- vs. intermediate-prognosis groups, P<0.0001, intermediate- vs. poor-prognosis groups).ConclusionsWe identified three predictors of the OS in patients with advanced BTC receiving GC therapy in this study, based on which we could classify the patients into three risk groups.
引用
收藏
页码:281 / 290
页数:10
相关论文
共 50 条
  • [41] FOLFIRINOX as a first-line chemotherapy for patients (pts) with advanced biliary tract cancer (BTC)
    Ulusakarya, A.
    Karray, W.
    Abdou, J.
    Karaboue, A.
    Haydar, M.
    Krimi, S.
    Gumus, Y.
    Almohamad, W.
    Goldschmidt, E.
    Biondani, P.
    Morere, J. F.
    ANNALS OF ONCOLOGY, 2018, 29 : 260 - 260
  • [42] Gemcitabine, Cisplatin, and Nab-Paclitaxel as a First-Line Therapy for Advanced Biliary Tract Cancers
    Sandeep Gedela
    Pritesh Munot
    Arvind Vaidyanathan
    Ritam Joarder
    Deepali Chaugule
    Manali Parulekar
    Chaitali Nashikkar
    Aayushi Ghadi
    Divya Vadodaria
    Mahesh Goel
    Shraddha Patkar
    Sarika Mandavkar
    Anant Ramaswamy
    Prabhat Bhargava
    Sujay Srinivas
    Vikas Ostwal
    Journal of Gastrointestinal Cancer, 2024, 55 : 263 - 269
  • [43] Gemcitabine, Cisplatin, and Nab-Paclitaxel as a First-Line Therapy for Advanced Biliary Tract Cancers
    Gedela, Sandeep
    Munot, Pritesh
    Vaidyanathan, Arvind
    Joarder, Ritam
    Chaugule, Deepali
    Parulekar, Manali
    Nashikkar, Chaitali
    Ghadi, Aayushi
    Vadodaria, Divya
    Goel, Mahesh
    Patkar, Shraddha
    Mandavkar, Sarika
    Ramaswamy, Anant
    Bhargava, Prabhat
    Srinivas, Sujay
    Ostwal, Vikas
    JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (01) : 263 - 269
  • [44] Management of first-line palliative chemotherapy for post-treatment metastasis after gemcitabine plus cisplatin induction chemotherapy: Gemcitabine plus cisplatin and non-gemcitabine plus cisplatin chemotherapy
    Yang, Zhen-Chong
    Du, Chao-Chao
    Liu, Ting
    Liu, Li-Ting
    Chen, Qiu-Yan
    Guo, Shan-Shan
    Mai, Hai-Qiang
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2022, 44 (01): : 113 - 121
  • [45] EFFICACY AND SAFETY OF GEMCITABINE PLUS CISPLATIN CHEMOTHERAPY FOR ADVANCED BILIARY TRACT CANCER: A RETROSPECTIVE STUDY
    Hirano, G.
    Takii, Y.
    Kamihira, T.
    Fujisawa, K.
    Ichiki, Y.
    Suzuki, T.
    Matsuo, T.
    Uraoka, S.
    Aoki, K. -I.
    Sakai, K. -I.
    Ogawa, R.
    Higuchi, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 121 - 121
  • [46] Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
    Lin, Zhong-Zhe
    Hsu, Chiun
    Chang, Yeun-Chung
    Yu, Chong-Jen
    Hsu, Chih-Hung
    Lin, Chia-Chi
    Cheng, Ann-Lii
    Yang, Pan-Chyr
    Yang, Chih-Hsin
    LUNG CANCER, 2008, 60 (02) : 215 - 221
  • [47] Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder cancer
    Cassier, P. A.
    Thevenet, C.
    Souquet, J.
    Ponchon, T.
    Baulieux, J.
    Partensky, C.
    Scoazec, J.
    Lombard-Bohas, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] A prospective, multicenter, phase II trial of albumin-paclitaxel plus cisplatin versus gemcitabine plus cisplatin in first-line treatment of advanced biliary tract tumors.
    Yang, Xiao
    Zhuang, Liang
    Dai, Yuhong
    Qiu, Hong
    Yuan, Xianglin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
    Park, Joon Oh
    Oh, Do-Youn
    Hsu, Chiun
    Chen, Jen-Shi
    Chen, Li-Tzong
    Orlando, Mauro
    Kim, Jong Seok
    Lim, Ho Yeong
    CANCER RESEARCH AND TREATMENT, 2015, 47 (03): : 343 - 361
  • [50] LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first-line chemotherapy
    Faloppi, Luca
    Del Prete, Michela
    Scartozzi, Mario
    Santini, Daniele
    Bianconi, Maristella
    Giampieri, Riccardo
    Cascinu, Stefano
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)